# US 6,727,234 B2 · Isoprenoid analog compounds and methods of making and use thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 6,727,234 B2
- Document ID: US6727234B2
- Status: Granted
- Kind: B2
- Application number: 10/116,737
- Filed: 2002-04-03
- Published: 2003-01-30
- Granted: 2004-04-27
- Earliest claimed: 2001-04-03
- Assignees: University of Iowa Research Foundation
- Inventors: David Wiemer; Raymond J. Hohl
- Web page: https://patentgrep.com/patent/US6727234B2

## CPC

- A61K 49/0021: {the fluorescent group being a small organic molecule}
- C07F 9/098: {Esters of polyphosphoric acids or anhydrides}
- C07F 9/113: with unsaturated acyclic alcohols
- C07F 9/3839: {Polyphosphonic acids}
- C07F 9/4015: {Esters of acyclic unsaturated acids}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07F: ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM (metal-containing porphyrins C07D487/22)

## Abstract

The invention provides compounds of formula I: wherein X, R1, R2, and n have any of the values defined in the specification, and their pharmaceutically acceptable salts. The compounds are useful, for example, for blocking prenylation transferase enzymes, for probing or diagnosing protein prenylation processes, and for treating cancer in a mammal. The invention also provides pharmaceutical compositions, processes for preparing compounds of formula I, and intermediates useful for the synthesis of compounds of formula I.

## Claims

### Claim 1

A compound of formula I:
wherein:
X is —NRa—;
R1 is aryl selected from the group consisting of phenyl, naphthyl and anthracenyl, which aryl is optionally substituted with one or more substituents independently selected from —COORb, —S(O)nNRbRb, halo, cyano, nitro, aryl, (C2-C6)alkenyl, —C(═O)NRbRb, —OC(═O)NRbRb, —NRbRb, or —S(O)nRb, where each Rb is independently hydrogen, (C1-C10)alkyl, or (C1-C10)alkanoyl;
R2 is
—O—P(═O)(—ORa)2,
—O—P(═O)(—ORa)—O—P(═O)(—ORa)2,
—CH2—O—P(═O)(—ORa)2,
—CH2—O—P(═O)(—ORa)—O—P(═O)(—ORa)2,
—CH2—P(═O)(—ORa)2,
—CH{—P(═O)(—ORa)2}2, or
—CH2—P(═O)(—ORa)—O—P(═O)(—ORa)2
each Ra is independently hydrogen, (C1-C10)alkyl, (C1-C10)alkanoyl, (C1-C10)alkanoyloxy, (C1-C10)alkoxycarbonyl, or —CH2—O—(C1-C10)alkanoyl; n is independently 1, 2, or 3; or a pharmaceutically acceptable salt thereof.

### Claim 2 (depends on 1)

The compound of claim 1 wherein R1 is substituted phenyl.

### Claim 3 (depends on 1)

The compound of claim 1 wherein R1 is phenyl substituted with —COORb.

### Claim 4 (depends on 1)

The compound of claim 1 wherein R1 is 2-methoxycarboxy phenyl.

### Claim 5 (depends on 1)

The compound of claim 1 wherein R1 is substituted naphthyl.

### Claim 6 (depends on 1)

The compound of claim 1 wherein R1 is naphthyl substituted with a —S(O)nNRbRb.

### Claim 7 (depends on 1)

The compound of claim 1 wherein R1 is naphthyl substituted at the 5-position with a —S(O)nNRbRb substituent.

### Claim 8 (depends on 1)

The compound of claim 1 wherein R1 is 5-N,N′-dimethylaminosulfonyl naphthy-1-yl.

### Claim 9 (depends on 1)

The compound of claim 1 wherein R2 is —O—P(═O)(—ORa)2.

### Claim 10 (depends on 1)

The compound of claim 1 wherein R2 is —O—P(═O)(—ORa)—O—P(═O)(—ORa)2.

### Claim 11 (depends on 1)

The compound of claim 1 wherein R2 is —CH2—O—P(═O)(—ORa)2.

### Claim 12 (depends on 1)

The compound of claim 1 wherein R2 is —CH2—O—P(═O)(—ORa)—O—P(═O)(—ORa)2.

### Claim 13 (depends on 1)

The compound of claim 1 wherein R2 is —CH2—P(═O)(—ORa)2.

### Claim 14 (depends on 1)

The compound of claim 1 wherein R2 is —CH{—P(═O)(—ORa)2}2.

### Claim 15 (depends on 1)

The compound of claim 1 wherein R2 is —CH2—P(═O)(—ORa)—O—P(═O)(—ORa)2.

### Claim 16 (depends on 1)

The compound of claim 1 wherein Ra is hydrogen.

### Claim 17 (depends on 1)

The compound of claim 1 wherein Ra is —C(═O)—CH3.

### Claim 18 (depends on 1)

The compound of claim 1 wherein Ra is —CH3.

### Claim 19 (depends on 1)

The compound of claim 1 wherein Ra is —CH2—O—(C1-C6)alkanoyl.

### Claim 20 (depends on 1)

The compound of claim 1 wherein Rb is hydrogen.

### Claim 21 (depends on 1)

The compound of claim 1 wherein Rb is —CH3.

### Claim 22 (depends on 1)

The compound of claim 1 wherein n is 1.

### Claim 23 (depends on 1)

The compound of claim 1 wherein n is 2.

### Claim 24 (depends on 1)

The compound of claim 1 wherein n is 3.

### Claim 25 (depends on 1)

The compound of claim 1 wherein X is —NH—.

### Claim 26 (depends on 1)

The compound of claim 1 wherein X is —N(CH3)—.

### Claim 27 (depends on 1)

A pharmaceutical composition comprising a compound as described in claim 1 and a pharmaceutically acceptable diluent or carrier.

### Claim 28 (depends on 1)

A method of inhibiting a prenylation transferase enzyme or synthase enzyme comprising contacting the enzyme with an effective amount of a compound as described in claim 1.
